Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Adjuvant chemotherapy for breast cancer--30 years later.

× No keyword cloud information.

17 in total

1. Lack of association between MDR1 C3435T polymorphism and chemotherapy response in advanced breast cancer patients: evidence from current studies.

Authors: Guodi Chen; Sheng Quan; Qiongge Hu; Liancong Wang; Xiaoping Xia; Jing Wu
Journal: Mol Biol Rep Date: 2011-12-09 Impact factor: 2.316

2. Th1 Immune Response Induction by Biogenic Selenium Nanoparticles in Mice with Breast Cancer: Preliminary Vaccine Model.

Authors: Mohammad Hossein Yazdi; Mehdi Mahdavi; Elnaz Faghfuri; Mohammad Ali Faramarzi; Zargham Sepehrizadeh; Zuhair Mohammad Hassan; Mehdi Gholami; Ahmad Reza Shahverdi
Journal: Iran J Biotechnol Date: 2015-06 Impact factor: 1.671

3. Retracted: Involvement of insulin-like growth factor-1 in chemotherapy-related cognitive impairment.

Authors: Teresita L Briones; Julie Woods; Magdalena Wadowska
Journal: Behav Brain Res Date: 2014-03-12 Impact factor: 3.332

4. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.

Authors: Lindsay M Morton; Graça M Dores; Margaret A Tucker; Clara J Kim; Kenan Onel; Ethel S Gilbert; Joseph F Fraumeni; Rochelle E Curtis
Journal: Blood Date: 2013-02-14 Impact factor: 22.113

5. The influence of non-clinical patient factors on medical oncologists' decisions to recommend breast cancer adjuvant chemotherapy.

Authors: T May Pini; Sarah T Hawley; Yun Li; Steven J Katz; Jennifer J Griggs
Journal: Breast Cancer Res Treat Date: 2012-06-21 Impact factor: 4.872

6. Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer.

Authors: Margot Burnell; Mark N Levine; Judith-Anne W Chapman; Vivien Bramwell; Karen Gelmon; Barbara Walley; Ted Vandenberg; Haji Chalchal; Kathy S Albain; Edith A Perez; Hope Rugo; Kathleen Pritchard; Patti O'Brien; Lois E Shepherd
Journal: J Clin Oncol Date: 2009-11-09 Impact factor: 44.544

Review 7. UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction.

Authors: Fumihiro Tanaka
Journal: Surg Today Date: 2007-10-25 Impact factor: 2.549

8. The GSTP1 105Val allele increases breast cancer risk and aggressiveness but enhances response to cyclophosphamide chemotherapy in North China.

Authors: Jie Ge; Ai-Xian Tian; Qing-Shan Wang; Peng-Zhou Kong; Yue Yu; Xiao-Qing Li; Xu-Chen Cao; Yu-Mei Feng
Journal: PLoS One Date: 2013-06-24 Impact factor: 3.240

9. Troglitazone reverses the multiple drug resistance phenotype in cancer cells.

Authors: Gerald F Davies; Bernhard H J Juurlink; Troy A A Harkness
Journal: Drug Des Devel Ther Date: 2009-09-21 Impact factor: 4.162

10. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.

Authors: George Fountzilas; Urania Dafni; Mattheos Bobos; Vassiliki Kotoula; Anna Batistatou; Ioannis Xanthakis; Christos Papadimitriou; Ioannis Kostopoulos; Triantafillia Koletsa; Eleftheria Tsolaki; Despina Televantou; Eleni Timotheadou; Angelos Koutras; George Klouvas; Epaminontas Samantas; Nikolaos Pisanidis; Charisios Karanikiotis; Ioanna Sfakianaki; Nicholas Pavlidis; Helen Gogas; Helena Linardou; Konstantine T Kalogeras; Dimitrios Pectasides; Meletios A Dimopoulos
Journal: BMC Cancer Date: 2013-03-28 Impact factor: 4.430